ケノデオキシコール酸
- 関
- chenodeoxycholic acid
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/01/23 22:34:10」(JST)
[Wiki en表示]
|
|
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (January 2009) |
| Chenodeoxycholic acid |
|
IUPAC name
chenodiol
OR
3α,7α-dihydroxy-5β-cholanic acid
OR
5β-cholanic acid-3α,7α-diol
OR
(R)-((3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy
-10,13-dimethylhexadecahydro-
1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid
|
| Identifiers |
| CAS number |
474-25-9 Y |
| ChemSpider |
9728 Y |
| UNII |
0GEI24LG0J Y |
| DrugBank |
DB06777 |
| KEGG |
C02528 N |
| ChEBI |
CHEBI:16755 N |
| ChEMBL |
CHEMBL240597 N |
| ATC code |
A05AA01 |
| Jmol-3D images |
Image 1 |
-
C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C
|
-
InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20-,22+,23+,24-/m1/s1 Y
Key: RUDATBOHQWOJDD-BSWAIDMHSA-N Y
InChI=1/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20-,22+,23+,24-/m1/s1
Key: RUDATBOHQWOJDD-BSWAIDMHBF
|
| Properties |
| Molecular formula |
C24H40O4 |
| Molar mass |
392.57 g/mol |
| Melting point |
165-167 °C
|
N (verify) (what is: Y/N?)
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
| Infobox references |
Chenodeoxycholic acid (also known as chenodesoxycholic acid and chenocholic acid) is a bile acid. It occurs as a white crystalline substance insoluble in water but soluble in alcohol and acetic acid, with melting point at 165-167 °C. Salts of this carboxylic acid are called chenodeoxycholates. Chenodeoxycholic acid is one of the 4 main organic acids produced by the liver.
Chenodeoxycholic acid is synthesized in the liver from cholesterol. It was first isolated in the domestic goose, hence the 'cheno' portion of its name (Greek: χήνα = goose) [1]
This compound, when altered by bacteria in the colon, will result in conversion to its secondary bile acid known as lithocholic acid. Both of these bile acids, in addition to the others, can be conjugated to taurine or glycine. Conjugation, a function carried out by the liver will result in a lowered pKa and therefore, the compounds will remain ionized. These ionized compounds will stay in the gastrointestinal tract until reaching the ileum where they will be reabsorbed. The purpose of this conjugation is to keep the bile acids in the tract until the end to facilitate lipid digestion all the way to the ileum.
In cases where bacteria overgrow in the small intestine, often due to a blind loop in the intestine retaining chyme in one place, the bacteria will de-conjugate the bile acids and therefore impede fat digestion and absorption. This can lead to steatorrhea.
Chenodeoxycholic acid and cholic acid are the most important human bile acids. Some other mammals synthesize predominantly deoxycholic acid.
Potential applications
The Australian biotechnology company Giaconda has developed a treatment for Hepatitis C infection that combines chenodeoxycholic acid with bezafibrate.
Chenodeoxycholic acid can be used in the treatment of cerebrotendinous xanthomatosis.
In supramolecular chemistry, molecular tweezers based on a chenodeoxycholic acid scaffold is a urea receptor [1] that can contain anions in its binding pocket in order of affinity: H2PO4- (dihydrogen phosphate) > Cl- > Br- > I- reflecting their basicities (tetrabutylammonium counter ion).[2]
References
- ^ Carey MC (December 1975). "Editorial: Cheno and urso: what the goose and the bear have in common". N. Engl. J. Med. 293 (24): 1255–7. doi:10.1056/NEJM197512112932412. PMID 1186807.
- ^ Molecular Tweezer Based on Chenodeoxycholic Acid:Synthesis, Anion Binding Properties Ki Soo Kim, Hong-Seok Kim Bulletin of the Korean Society 1411-1413 2004 Article
|
Bile and liver therapy (A05)
|
|
| Bile therapy |
- bile acid (Chenodeoxycholic acid
- Cholic acid
- Ursodeoxycholic acid)
- Nicotinyl methylamide
- Piprozolin
- Hymecromone
- Cyclobutyrol
|
|
| Liver therapy |
- Arginine glutamate
- Silymarin
- Citiolone
- Epomediol
- Ornithine oxoglutarate
- Tidiacic arginine
- Glycyrrhizin
|
|
|
|
anat (t, g, p)/phys/devp/enzy
|
noco/cong/tumr, sysi/epon
|
proc, drug (A2A/2B/3/4/5/6/7/14/16), blte
|
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 胆石の疫学および危険因子 epidemiology of and risk factors for gallstones
- 2. 妊婦における胆石症 gallstone disease in pregnant women
English Journal
- Retention data of bile acids and their oxo derivatives in characterization of pharmacokinetic properties and in silico ADME modeling.
- Trifunović J1, Borčić V2, Vukmirović S2, Kon SG3, Mikov M2.
- European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.Eur J Pharm Sci.2016 Sep 20;92:194-202. doi: 10.1016/j.ejps.2016.07.011. Epub 2016 Jul 14.
- PURPOSE: Information on ADME properties of examined bile acids and their oxo derivatives are scarce, although the interest for bile acids and their use in nanochemistry and macromolecular chemistry is increasing. The purpose of this research was to evaluate the lipophilicity, a crucial physicochemic
- PMID 27423261
- Transporter-targeted cholic acid-cytarabine conjugates for improved oral absorption.
- Zhang D1, Li D2, Shang L3, He Z1, Sun J4.
- International journal of pharmaceutics.Int J Pharm.2016 Sep 10;511(1):161-9. doi: 10.1016/j.ijpharm.2016.06.139. Epub 2016 Jul 1.
- Cytarabine has a poor oral absorption due to its rapid deamination and poor membrane permeability. Bile acid transporters are highly expressed both in enterocytes and hepatocytes and to increase the oral bioavailability and investigate the potential application of cytarabine for liver cancers, a tra
- PMID 27377011
- The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes.
- Mathavan S1, Chen-Tan N2, Arfuso F3, Al-Salami H1.
- Artificial cells, nanomedicine, and biotechnology.Artif Cells Nanomed Biotechnol.2016 Sep;44(6):1508-19. doi: 10.3109/21691401.2015.1058807. Epub 2015 Jul 25.
- Gliclazide (G) is used to treat type 2 diabetes (T2D), and also has anti-platelet, anti-radical, and anti-inflammatory effects. G has poor water solubility and high inter-individual variations in absorption, limiting its application in type 1 diabetes (T1D). The bile acid, chenodeoxycholic acid (CDC
- PMID 26212118
Japanese Journal
- Alterations in the Detergent-Induced Membrane Permeability and Solubilization of Saturated Phosphatidylcholine/Cholesterol Liposomes: Effects of Poly(ethylene glycol)-Conjugated Lipid
- Inhibition of Hepatocyte Growth Factor Production in Human Fibroblasts by Ursodeoxycholic Acid(Pharmacology)
- Biological & pharmaceutical bulletin 28(4), 619-624, 2005-04-01
- NAID 10016661983
- Binding of bile salts to soluble and insoluble dietary fibers of seaweeds
Related Links
- Sodium chenodeoxycholate ≥97%; CAS Number: 2646-38-0; Synonym: 3α,7α-Dihydroxy-5β-cholanic acid, 5β-Cholanic acid-3α,7α-diol, Chenodeoxycholic acid sodium salt, Chenodesoxycholic acid, Chenodiol; Linear Formula ...
- Sodium chenodeoxycholate is a bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic ...
Related Pictures
★リンクテーブル★
[★]
- 英
- chenodeoxycholic acid CDCA、chenodeoxycholate
- 商
- ケノコール、コラーザ、レガレン、チノ
- 関
- 胆汁酸、胆石溶解剤
[★]
タウロケノデオキシコール酸
- 関
- taurochenodeoxycholic acid